Epidiolex approved for sale in Canada
Canada’s federal health regulator has approved Jazz Pharmaceuticals Canada’s cannabinoid-based medicine Epidiolex as an adjunctive therapy for certain rare and severe forms of epilepsy, allowing the company to bring to market a clinically tested drug with global sales that dwarf those of the nation’s entire medical cannabis industry. Epidiolex is the top-selling clinically proven cannabinoid-based medicine in […]
Go to Source
Powered by WPeMatico
